Biotech News
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
ir.cvrx.com2026-05-06 15:02 EST
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11%
